See other companies on Welcome to the Jungle
NuvoAir
Specialty care for patients with cardiopulmonary conditions
- 21-100 employees
- Healthcare
- B2B
- Deep Tech
- SaaS
- MedTech
- Downtown Crossing, Boston, MA
Jump to section
Company mission
To fundamentally change the way healthcare is delivered.
17% employee growth in 12 months
Our take
Cardiopulmonary conditions are a major burden on healthcare systems, with one in two seniors suffering from heart or lung conditions. Established in 2015, NuvoAir offers a digital healthcare platform to help improve the level of care for patients suffering from these conditions.
NuvoAir has developed a range of services to improve patient lung health, along with in-depth data analysis which makes use of remotely-collected biomarkers to drive clinical decision-making. Its platform leads to an 80% decrease in hopsitalizations and a greatly increased quality of life for patients, and the company has grown rapidly as a result, seeing 500% growth in 2021 alone.
Its latest funding will accelerate the expansion of NuvoAir’s digital care platform in the U.S and Europe, while focusing on speeding up the development of new products and services.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Retirement plan with a company match
- Hybrid work environment that promotes collaboration and stems from a “trust first” mentality
- Health benefits, as well as a Wellness and Gym Reimbursement
- Generous time off that encourages personal time spent with family and friends
- Opportunities for learning & development
- Equity that’s venture-backed by top VC firms
Company values
- Practice confident humility - We aim to hold ourselves to the highest standards of humility, curiosity, transparency, and personal development
- Act like an owner - Ownership means we speak up, share ideas, give feedback, and are all accountable for growth
- Focus on what matters - Creating meaningful solutions to challenging healthcare problems requires simplicity, clarity, and using our unique leverage
- Build to learn - Failing courageously is a virtue that drives learning and stems from an innovative spirit
- Be patient obessed - Every decision is made with our main focus in mind - improving the lives of patients
Funding (last 2 of 4 rounds)
Jan 2022
$11m
SERIES A
Jun 2021
$12m
SERIES A
Total funding: $28.2m
Leadership
Lorenzo Consoli
(CEO)Previously co-founded Copharma, acting as CEO. Experience as a Business Analyst for Indesit Company and Value Partners (Intern). Spent nearly 6 years at Novartis, eventually as Global Innovation Director of Digital Solutions.